Centessa Pharmaceuticals Limited (CNTA): Price and Financial Metrics
GET POWR RATINGS... FREE!
CNTA Stock Price Chart Interactive Chart >
CNTA Price/Volume Stats
|Current price||$4.00||52-week high||$13.83|
|Prev. close||$3.89||52-week low||$2.88|
|Day high||$4.01||Avg. volume||197,071|
|50-day MA||$3.90||Dividend yield||N/A|
|200-day MA||$5.65||Market Cap||378.38M|
Centessa Pharmaceuticals Limited (CNTA) Company Bio
Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.
Most Popular Stories View All
CNTA Latest News Stream
|Loading, please wait...|
CNTA Latest Social Stream
View Full CNTA Social Stream
Latest CNTA News From Around the Web
Below are the latest news stories about CENTESSA PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate CNTA as an investment opportunity.
While institutions own 29% of Centessa Pharmaceuticals plc (NASDAQ:CNTA), private equity firms are its largest shareholders with 42% ownership
To get a sense of who is truly in control of Centessa Pharmaceuticals plc ( NASDAQ:CNTA ), it is important to...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
– Company highlights three significant near-term milestones – – Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 observation study on track to begin this quarter – – Data readout of SerpinPC Phase 2a OLE Study with additional 18-months of continued subcutaneous treatment at American Society of Hematology (ASH) Annual Meeting in December 2022 – – IND submission for LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody, on track for late 2022 – – Cash runway
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentationBOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that new data from an additional 18-months of continued treatment with SerpinPC from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC for the treatment of hemophilia, has been accepted for oral presenta
BOSTON and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies London Healthcare ConferenceDate: Thursday, November 17, 2022Location: London, UKFireside Chat: 10:55 AM GMT Event: Evercore ISI HealthCONx Conference (V
Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)
– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) –– Company recognizes World Narcolepsy Day on September 22nd – BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that non-clinical data from its oral orexin receptor 2 (OX2R) agonist discovery pipeline have been accepted for poster presentation at the 26th Conference of the European Sleep Research Society meeting (S
CNTA Price Returns